Branebrutinib
- Generic Name
- Branebrutinib
- Drug Type
- Small Molecule
- Chemical Formula
- C20H23FN4O2
- CAS Number
- 1912445-55-6
- Unique Ingredient Identifier
- 7LBRZUYSHU
- Background
Branebrutinib is under investigation in clinical trial NCT02705989 (Safety, Tolerability and Relative Bioavailability Study of BMS-986195 in Healthy Subjects).
A Study to Assess Relative Bioavailability of Branebrutinib, From a Tablet Formulation to the Capsule Formulation, the Effect of Food on the Bioavailability of Branebrutinib From a Tablet Formulation, and the Safety and Drug Levels of Branebrutinib From a Tablet Formulation in Healthy Participants
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2023-02-15
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 56
- Registration Number
- NCT05303220
- Locations
- 🇺🇸
Local Institution - 0001, Miami, Florida, United States
A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic Dermatitis
- Conditions
- Dermatitis, Atopic
- Interventions
- First Posted Date
- 2021-08-20
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 17
- Registration Number
- NCT05014438
- Locations
- 🇩🇪
Private Practice - Dr. Ralph von Kiedrowski, Selters, Germany
🇺🇸Local Institution - 0008, Skokie, Illinois, United States
🇺🇸Local Institution - 0078, Philadelphia, Pennsylvania, United States
Study to Assess the Effect of Branebrutinib on the Drug Levels of Rosuvastatin in Healthy Participants
- First Posted Date
- 2020-08-17
- Last Posted Date
- 2022-03-10
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 22
- Registration Number
- NCT04515628
- Locations
- 🇺🇸
ICON (LPRA) - Salt Lake, Salt Lake City, Utah, United States
Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis
- Conditions
- Autoimmune DisorderRheumatoid ArthritisSystemic Lupus ErythematosusPrimary Sjögren's Syndrome
- Interventions
- First Posted Date
- 2019-12-05
- Last Posted Date
- 2024-01-16
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 119
- Registration Number
- NCT04186871
- Locations
- 🇺🇸
Local Institution - 0083, Spokane, Washington, United States
🇺🇸Local Institution - 0024, Encino, California, United States
🇫🇷Local Institution - 0075, Brest, France
The Effect of BMS-986195 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2017-08-25
- Last Posted Date
- 2020-03-20
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 58
- Registration Number
- NCT03262740
- Locations
- 🇺🇸
Miami Research Associates, South Miami, Florida, United States
🇺🇸PRA Health Sciences, Salt Lake City, Utah, United States
A Study of BMS-986195 in Healthy Male Subjects
- First Posted Date
- 2017-08-10
- Last Posted Date
- 2018-01-05
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 24
- Registration Number
- NCT03245515
- Locations
- 🇳🇱
Local Institution, Groningen, Netherlands
Effects of Concomitant Administration of BMS-986195 on Methotrexate, Caffeine, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2017-04-27
- Last Posted Date
- 2017-12-15
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 26
- Registration Number
- NCT03131973
- Locations
- 🇺🇸
PPD Development, LP, Austin, Texas, United States
Safety, Tolerability and Relative Bioavailability Study of BMS-986195 in Healthy Subjects
- First Posted Date
- 2016-03-11
- Last Posted Date
- 2019-01-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 439
- Registration Number
- NCT02705989
- Locations
- 🇦🇺
Local Institution, Melbourne, Victoria, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.